Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 27964


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27964

License Grant
The Irish Licensee entered into a purchase and license agreement with the Irish Licensor, to license several oral drug delivery technologies, including a large intellectual property portfolio, which included the GIPET and GIRES delivery technologies, as well as a pipeline of future products and technologies relating to oral vaccine delivery and targeting ligands.
Field of Use
The rights granted apply to the healthcare industry relating in the development of improved oral dosage forms of drugs with poor bioavailability.

IPSCIO Record ID: 248403

License Grant
This Agreement provides for a feasibility and phase I study to be conducted to study the feasibility of oral delivery of the product cyclobenzoprine using Licensors delivery technology.

Licensor grants the exclusive option to obtain an exclusive, worldwide license under the Licensor Intellectual Property for the further development and commercialization of the Product.

License Property
Licensors property is LipralTM technology.   Lipralâ„¢ is for improved oral absorption of poorly water soluble drugs and elimination of food effects on absorption.

The Licensees property relates to very low dose cyclobenzoprine (VLD-cyclo).

Field of Use
The field is for improving absorption of poorly water-soluble compounds.

IPSCIO Record ID: 29094

License Grant
A  jury ruled in the U.S. District Court for the District of Delaware that the Licensee had infringed a patent owned by the Irish Licensor in relation to the application of NanoCrystal® technology.
License Property
NanoCrystal technology can improve the bioavailability of drugs by transforming them into nanometer-sized particles that can be used to create more effective and convenient dosage forms such as tablets, capsules, liquids, and powders. The Licensee has announced its intention to appeal the ruling. Consequently, pending final resolution of this matter, no settlement amount has been recognized in the interim financial statements.

IPSCIO Record ID: 6044

License Grant
The Licensee acquired the Licensor, a manufacturer of a patented soft-textured chew technology.  The patented technology allows for easy compliance and masking of bitter tasting, as well as difficult to swallow drugs usually indicative of typical oral dosage delivery systems.
Field of Use
Field of use relates to the medical industry.

IPSCIO Record ID: 5407

License Grant
The Licensor has entered into agreement with the Licensee which is developing several potential products which are vaccine based.
Field of Use
The Licensee wishes to use a combination of liposomes or cochleates in conjunction with Sendai vital proteins and its HIV synthetic peptides to create an EradicAide HIV Vaccine.
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form:
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.

To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.